EPCAM and neoplasm: Based on previous transcriptomic and epigenomic studies of skin SCCs performed by the Blanpain group, Debaugnies et al. analyzed the potential regulators of chemoresistance in EPCAM+ and EPCAM− tumor cells and found that RHOJ was highly expressed in EPCAM− tumor cells.